Evidence map›Paper›PMID 41608574›Full record

ReviewTheranostics2026

Synergistic terahertz platforms for precision oncology.

Yan Chen, Xiaodan Kou, Jing Zou, Peng Chen, Junfeng Liu, Yanru Gu, Min Zhuang, Hongtao Xiao, Yuying Li, Man Lu and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yan ChenDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Xiaodan KouDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Jing ZouDepartment of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610000, China.
Peng ChenDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Junfeng LiuDepartment of Interventional Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Yanru GuDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Min ZhuangDepartment of Ultrasound, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Medicine & Laboratory of Transitional Research in Ultrasound Theranostics, Chengdu, 610000, China.
Hongtao XiaoDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Yuying LiDepartment of Respiratory Critical Care, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Man LuDepartment of Ultrasound, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Medicine & Laboratory of Transitional Research in Ultrasound Theranostics, Chengdu, 610000, China.
Shugang QinDepartment of Experimental Research, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

THz technology is expected to provide breakthroughs for precision oncology due to its physical nature, such as non-ionizing radiation nature, sensitivity to water and fingerprint recognition. Yet, its clinical application is severely limited due to their drawbacks: shallow penetration depth, difficult interpretation and sensitivity. This review examines recent interdisciplinary advances that integrate THz technology with materials science, nanotechnology, artificial intelligence (AI), computational modeling, gene editing, and microfluidics to develop intelligent diagnostic and therapeutic systems capable of supporting the full oncology continuum-from tumor imaging and biomarker detection to treatment monitoring and drug delivery assessment. For example, combining THz with metamaterials or nanostructures enhances sensitivity for trace-level biomarker detection; AI algorithms enable rapid, accurate interpretation of complex spectral data for automated diagnosis; and convergence with microfluidics and CRISPR-based systems has led to ultra-sensitive liquid biopsy platforms. These integrated approaches not only address existing technical barriers but also open pathways toward multifunctional theranostic systems with practical clinical utility. By fostering cross-disciplinary collaboration, THz technology can be further optimized to enable more accurate, effective, and personalized cancer care, transforming its potential from foundational research into real-world clinical impact.

Indexed as

Medical OncologyNeoplasmsPrecision MedicineTerahertz ImagingArtificial IntelligenceHumansNanotechnologyTheranostic Nanomedicineartificial intelligencecancer therapyprecision oncologyterahertztumor imaging

Identifiers

PMID41608574
PMCPMC12846777

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.